Format

Send to

Choose Destination
Cancer Commun (Lond). 2019 Nov 21;39(1):78. doi: 10.1186/s40880-019-0423-3.

Long-lasting responses after discontinuation of nivolumab treatment for reasons other than tumor progression in patients with previously treated, advanced non-small cell lung cancer.

Author information

1
Respiratory Medicine, Kanazawa University Hospital, Takara-machi 13-1, Kanazawa, Ishikawa, 920-8641, Japan. hkimura3625@staff.kanazawa-u.ac.jp.
2
Respiratory Medicine, National Hospital Organization Kanazawa Medical Center, Kanazawa, Ishikawa, 920-8650, Japan.
3
Respiratory Medicine, Komatsu Municipal Hospital, Komatsu, Ishikawa, 923-8560, Japan.
4
Respiratory Medicine, Fukui-ken Saiseikai Hospital, Fukui, Fukui, 918-8503, Japan.
5
Respiratory Medicine, Ishikawa Prefectural Central Hospital, Kanazawa, Ishikawa, 920-8530, Japan.
6
Internal Medicine, Keiju Medical Center, Nanao, Ishikawa, 926-8605, Japan.
7
Respiratory Medicine, Kanazawa University Hospital, Takara-machi 13-1, Kanazawa, Ishikawa, 920-8641, Japan.
8
Regional Respiratory Symptomatology, Kanazawa University Graduate School of Medical Science, Kanazawa, Ishikawa, 920-8641, Japan.

Supplemental Content

Full text links

Icon for BioMed Central Icon for PubMed Central
Loading ...
Support Center